SEC Form 4 · accession 0001209191-17-046029
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Amit Sachdev
Officer — EVP, CRO
Period of report
Jul 19, 2017
Accepted (ET)
Jul 21, 2017 · 8:07 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 19, 2017 | M | 20,000 | $77.31 | A | 119,335 | D | |
| Common Stock | Jul 19, 2017 | S | 20,000 | $161.00 | D | 99,335 | D | |
| Common StockF2,F3 | Jul 21, 2017 | S | 800 | $158.05 | D | 98,535 | D | |
| Common StockF3,F4 | Jul 21, 2017 | S | 1,300 | $158.90 | D | 97,235 | D | |
| Common StockF3,F5 | Jul 21, 2017 | S | 500 | $160.04 | D | 96,735 | D | |
| Common StockF3,F6 | Jul 21, 2017 | S | 4,461 | $161.44 | D | 92,274 | D | |
| Common StockF3,F7 | Jul 21, 2017 | S | 1,564 | $162.07 | D | 90,710 | D | |
| Common Stock | holding | — | — | — | 882 | I | 401(k) |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF8 | $77.31 | Jul 19, 2017 | M | 20,000 | A | — | Feb 4, 2024 | Common Stock | 20,000 | 21,250 | D |
Explanation of responses
- F1Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1.
- F2Open market sales reported on this line occurred at a weighted average price of $158.05 (range $157.48 to $158.37).
- F3Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $158.90 (range $158.61 to $159.53).
- F5Open market sales reported on this line occurred at a weighted average price of $160.04 (range $159.64 to $160.25).
- F6Open market sales reported on this line occurred at a weighted average price of $161.44 (range $160.90 to $161.89)
- F7Open market sales reported on this line occurred at a weighted average price of $162.07 (range $161.90 to $162.43).
- F8The option vests in 16 quarterly installments from 02/05/2014.